StockData

Carlsmed vs TELA Bio

CARL and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CARL and TELA compare

Carlsmed is the larger company, worth 14 times as much as TELA Bio ($484M against $34.2M).

Carlsmed grew revenue faster over the last twelve months (65.4% versus 6.1% for TELA Bio).

TELA Bio keeps more of each dollar of sales as profit, with a net margin of −51.5% compared with −57.4% at Carlsmed.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCARLTELA
Size and price
Market cap$484M$34.2M
Share price$17.74$0.762
Change, 1 year35.3%−23.7%
Change, 5 years–−93.8%
Beta (5Y)2.472.04
Employees24218
StockData Score
Total score55
Valuation score01 (better)
Growth score3 (better)2
Performance score01 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S7.7×0.4× (better)
P/B5.7×–
FCF yield−7.1% (better)−92.4%
Fair value$8.14–
Margin of safety−118%–
Growth
Revenue growth (TTM)65.4% (better)6.1%
Revenue growth, 5Y average–34.5%
Profitability
Gross margin76.6% (better)67.8%
Operating margin−61.1%−42.6% (better)
Net margin−57.4%−51.5% (better)
FCF margin−54.6%−39.6% (better)
Return on equity−6197%–
Return on invested capital–−212%
Financial health
Interest coverage−29.0×−4.9× (better)
Current ratio8.84 (better)2.99
Altman Z-score7.58 (better)−9.41
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions20.9%70.5%
Held by insiders81.1%41.0%
Insider net buying, 12 months−$2.7M$186K (better)
Short interest, % of float24.0%2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.